Amylin acts in the central nervous system to increase sympathetic nerve activity

Endocrinology

Volumn 154, Issue 7, 2013, Pages 2481-2488

  Fernandes Santos, Caroline ^a,b   Zhang, Zhongming ^a   Morgan, Donald A ^a   Guo, Deng Fu ^a   Russo, Andrew F ^a   Rahmouni, Kamal ^a  

^a UNIVERSITY OF IOWA   (United States)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; PROTEIN C FOS; RECEPTOR ACTIVITY MODIFYING PROTEIN 1;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ARTICLE; BODY TEMPERATURE; BODY WEIGHT; BRAIN STEM; BROWN ADIPOSE TISSUE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DORSOMEDIAL HYPOTHALAMIC NUCLEUS; EVOKED RESPONSE; FOOD INTAKE; HYPOTHALAMUS; KIDNEY NERVE; MALE; MOUSE; NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL ROOT; THERMOGENESIS;

ADIPOSE TISSUE, BROWN; ANIMALS; BODY TEMPERATURE; BODY WEIGHT; CENTRAL NERVOUS SYSTEM; EATING; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENTRICULAR; ISLET AMYLOID POLYPEPTIDE; MALE; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTOR ACTIVITY-MODIFYING PROTEIN 1; SYMPATHETIC NERVOUS SYSTEM;

EID: 84879324190     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-2172     Document Type: Article

References (52)

1. Westermark P, Wernstedt C, Wilander E, Sletten K. A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun. 1986;140:827-831. (Pubitemid 17207764)
2. Clark A, Cooper JG, Lewis CE, et al. Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet. 1987;2:231-234.
3. Johnson KH, O'Brien TD, Hayden DW, et al. Immunolocalization of islet amyloid polypeptide (IAPP) in pancreatic β-cells by means of peroxidase-antiperoxidase (PAP) and protein A-gold techniques. Am J Pathol. 1988;130:1-8. (Pubitemid 18044828)
4. Lukinius A, Wilander E, Westermark GT, Engström U, Westermark P. Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia. 1989;32:240-244. (Pubitemid 19136367)
5. Butler PC, Chou J, Carter WB, et al. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes. 1990;39:752-756. (Pubitemid 20218978)
6. Butler PC, Chou J, Wang YN, et al. Amylin is co-secreted with insulin in man. Clin Res. 1990;38:A307.
7. Pieber TR, Roitelman J, Lee Y, Luskey KL, Stein DT. Direct plasma radioimmunoassay for rat amylin-(1-37): concentrations with acquired and genetic obesity. Am J Physiol. 1994;267:E156-E164.
8. Balasubramaniam A, Renugopalakrishnan V, Stein M, Fischer JE, Chance WT. Syntheses, structures and anorectic effects of human and rat amylin. Peptides. 1991;12:919-924.
9. Chance WT, Balasubramaniam A, Stallion A, Fischer JE. Anorexia following the systemic injection of amylin. Brain Res. 1993;607:185-188. (Pubitemid 23104964)
10. Young AA, Cooper GJS, Carlo P, Rink TJ, Wang MW. Response to Intravenous Injections of Amylin and Glucagon in Fasted, Fed, and Hypoglycemic Rats. Am J Physiol. 1993;264:E943-E950. (Pubitemid 23198571)
11. Arnelo U, Permert J, Adrian TE, Larsson J, Westermark P, Reidelberger RD. Chronic infusion of islet amyloid polypeptide causes anorexia in rats. Am J Physiol Reg Integ Comp Physiol. 1996;40:R1654-R1659.
12. Morley JE, Flood JF. Amylin Decreases Food-Intake in Mice. Peptides. 1991;12:865-869.
13. Bhavsar S, Watkins J, Young A. Synergy between amylin and cholecystokinin for inhibition of food intake in mice. Physiol Behav. 1998;64:557-561. (Pubitemid 28458854)
14. Reidelberger RD, Haver AC, Arnelo U, Smith DD, Schaffert CS, Permert J. Amylin receptor blockade stimulates food intake in rats. Am J Physiol Reg Integ Comp Physiol. 2004;287:R568-R574. (Pubitemid 39095931)
15. Lutz TA, Rossi R, Althaus J, Del Prete E, Scharrer E. Amylin reduces food intake more potently than calcitonin gene-related peptide (CGRP) when injected into the lateral brain ventricle in rats. Peptides. 1998;19:1533-1540. (Pubitemid 29015894)
16. Mack C, Wilson J, Athanacio J, et al. Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight. Am J Physiol Regul Integr Comp Physiol. 2007;293:R1855-R1863. (Pubitemid 350085661)
17. Rushing PA, Hagan MM, Seeley RJ, Lutz TA, Woods SC. Amylin: a novel action in the brain to reduce body weight. Endocrinology. 2000;141:850-853. (Pubitemid 32250511)
18. Rushing PA, Hagan MM, Seeley RJ, et al. Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology. 2001;142:5035-5038. (Pubitemid 33022381)
19. Cancello R, Tounian A, Poitou Ch, Clément K. Adiposity signals, genetic and body weight regulation in humans. Diabetes Metab. 2004;30:215-227. (Pubitemid 38917451)
20. Banks WA, Kastin AJ, Maness LM, Huang W, Jaspan JB. Permeability of the blood-brain barrier to amylin. Life Sci. 1995;57:1993-2001.
21. Banks WA, Kastin AJ. Differential permeability of the blood-brain barrier to two pancreatic peptides: Insulin and amylin. Peptides. 1998;19:883-889. (Pubitemid 28312286)
22. Vanrossum D, Menard DP, Fournier A, Stpierre S, Quirion R. Autoradiographic Distribution and Receptor-Binding Profile of [I-125] Bolton Hunter-Rat Amylin Binding-Sites in the Rat-Brain. J Pharmacol Exp Ther. 1994;270:779-787. (Pubitemid 24271395)
23. Rowland NE, Crews EC, Gentry RM. Comparison of Fos induced in rat brain by GLP-1 and amylin. Regul Pept. 1997;71:171-174. (Pubitemid 27433677)
24. Sexton PM, Paxinos G, Kenney MA, Wookey PJ, Beaumont K. In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience. 1994;62:553-567. (Pubitemid 24306678)
25. Paxinos G, Chai SY, Christopoulos G, et al. In vitro autoradiographic localization of calcitonin and amylin binding sites in monkey brain. J Chem Neuroanat. 2004;27:217-236. (Pubitemid 38903276)
26. Christopoulos G, Perry KJ, Morfis M, et al. Multipleamylin receptorsarise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol. 1999;56:235-242. (Pubitemid 29309833)
27. Leuthäuser K, Gujer R, Aldecoa A, et al. Receptor-activity-modifying protein 1 forms heterodimers with two G-protein-coupled receptors to define ligand recognition. Biochem J. 2000;351:347-351.
28. Hay DL, Christopoulos G, Christopoulos A, Sexton PM. Amylin receptors: molecular composition and pharmacology. Biochem Soc Trans. 2004;32:865-867. (Pubitemid 39524399)
29. Udawela M, Hay DL, Sexton PM. The receptor activity modifying protein family of G protein coupled receptor accessory proteins. Semin Cell Dev Biol. 2004;15:299-308. (Pubitemid 38581998)
30. Hay DL, Poyner DR, Sexton PM. GPCR modulation by RAMPS. Pharmacol Ther. 2006;109:173-197. (Pubitemid 41740820)
31. Barth SW, Riediger T, Lutz TA, Rechkemmer G. Peripheral amylin activates circumventricular organs expressing calcitonin receptor A/B subtypes and receptor-activity modifying proteins in the rat. Brain Res. 2004;997:97-102. (Pubitemid 38058539)
32. Dulloo AG. Biomedicine. A sympathetic defense against obesity. Science. 2002;297:780-781. (Pubitemid 34839615)
33. Zhang Z, Winborn CS, Marquez de Prado B, Russo AF. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci. 2007;27:2693-2703. (Pubitemid 46393588)
34. Rahmouni K, Morgan DA, Morgan GM, et al. Hypothalamic PI3K and MAPK differentially mediate regional sympathetic activation to insulin. J Clin Invest. 2004;114:652-658. (Pubitemid 39578755)
35. Riediger T, Zuend D, Becskei C, Lutz TA. The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut-brain axis. Am J Physiol Regul Integr Comp Physiol. 2004;286:R114-R122. (Pubitemid 38055899)
36. Malpas SC. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev. 2010;90:513-557.
37. Zhang Z, Liu X, Morgan DA, et al. Neuronal receptor activity-modifying protein 1 promotes energy expenditure in mice. Diabetes. 2011;60:1063-1071.
38. Lutz TA. Amylinergic control of food intake. Physiol Behav. 2006;89:465-471. (Pubitemid 44634569)
39. Riediger T, Schmid HA, Lutz T, Simon E. Amylin potently activates AP neurons possibly via formation of the excitatory second messenger cGMP. Am J Physiol Regul Integr Comp Physiol. 2001;281:R1833-R1843.
40. Becskei C, Grabler V, Edwards GL, Riediger T, Lutz TA. Lesion of the lateral parabrachial nucleus attenuates the anorectic effect of peripheral amylin and CCK. Brain Res. 2007;1162:76-84. (Pubitemid 47088378)
41. Chance WT, Balasubramaniam A, Zhang FS, Wimalawansa SJ, Fischer JE. Anorexia following the intrahypothalamic administration of amylin. Brain Res. 1991;539:352-354.
42. Roth JD, Hughes H, Kendall E, Baron AD, Anderson CM. Antiobesity effects of the β-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology. 2006;147:5855-5864. (Pubitemid 44833502)
43. Bouali SM, Wimalawansa SJ, Jolicoeur FB. In vivo central actions of rat amylin. Regul Pept. 1995;56:167-174.
44. Osaka T, Tsukamoto A, Koyama Y, Inoue S. Central and peripheral administration of amylin induces energy expenditure in anesthetized rats. Peptides. 2008;29:1028-1035.
45. Kailasam MT, Parmer RJ, Tyrell EA, Henry RR, O'Connor DT. Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk. J Hypertens. 2000;18:1611-1620.
46. Novials A, Rodriguez-Mañas L, Chico A, El Assar M, Casas S, Gomis R. Amylin and hypertension: association of an amylin -G132A gene mutation and hypertension in humans and amylin-induced endothelium dysfunction in rats. J Clin Endocrinol Metab. 2007;92:1446-1450. (Pubitemid 46556424)
47. Hou X, Sun L, Li Z, et al. Associations of amylin with inflammatory markers and metabolic syndrome in apparently healthy Chinese. PLoS One. 2011;6:e24815.
48. Haynes JM, Hodgson WC, Cooper ME. Rat amylin mediates a pressor response in the anaesthetised rat: implications for the association between hypertension and diabetes mellitus. Diabetologia. 1997;40:256-261. (Pubitemid 27096548)
49. Aronne LJ, Halseth AE, Burns CM, Miller S, Shen LZ. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity (Silver Spring). 2010;18:1739-1746.
50. Seth R, Knight WD, Overton JM. Combined amylin-leptin treatment lowers blood pressure and adiposity in lean and obese rats. Int J Obes (Lond). 2011;35:1183-1192.
51. Young AA, Rink TJ, Wang MW. Dose response characteristics for the hyperglycemic, hyperlactemic, hypotensive and hypocalcemic actions of amylin and calcitonin gene-related peptide-I (CGRPα) in the fasted, anaesthetized rat. Life Sci. 1993;52:1717-1726.
52. Roth JD, Maier H, Chen S, Roland BL. Implications of Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications. Arch Neurol. 2009;66:306-310.